PremiumRatingsAN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Strong Financial Position AN2 Therapeutics Reports 2024 Financials and Pipeline Progress AN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Stable Financial Outlook PremiumThe FlyAN2 Therapeutics submits amended EBO-301 trial statistical analysis plan to FDA Citizens JMP healthcare analysts hold an analyst/industry conference call JMP Securities healthcare analysts hold an analyst/industry conference call PremiumThe FlyAN2 Therapeutics adopts limited duration stockholder rights plan AN2 Therapeutics reports Q2 EPS (48c), consensus (59c) Morning Movers: Iteris skyrockets following take-private agreement